CRISPR-Associated Transposase Genome Editing Specificity Efficiency
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current CRISPR-Cas systems for sequence-specific nucleic acid modification face challenges in achieving high specificity and efficiency, particularly in eukaryotic cells, where precise genome editing is required for applications such as disease resistance and recombination enhancement.
Innovation Solution
The use of recombinant nucleic acids encoding CRISPR-associated transposases with specific amino acid sequences, such as those from SEQ ID NOs: 124-246 and 275-287, combined with guide RNAs, to introduce targeted double-strand breaks in eukaryotic cells, facilitating sequence-specific modification and recombination events.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If CRISPR-Cas systems are used for sequence-specific nucleic acid modification, then specificity is improved, but efficiency is worsened in eukaryotic cells
Solution Approach 1:
The patent combines CRISPR-Cas systems with transposase enzymes to create a hybrid system that integrates the targeting precision of CRISPR with the genomic integration capability of transposases. This merging allows the system to achieve both high specificity through guide RNA-directed targeting and high efficiency through transposase-mediated DNA insertion, resolving the contradiction between specificity and efficiency in eukaryotic genome editing.
Solution Approach 2:
The invention creates a composite enzymatic system by fusing or coordinating CRISPR-Cas nucleases with transposase enzymes. This composite approach combines the sequence-specific recognition capability of CRISPR with the efficient genomic integration function of transposases, enabling simultaneous achievement of high specificity and high efficiency in nucleic acid modification within eukaryotic cells.
2Manufacturing precision
If CRISPR-Cas systems are used for genome editing, then precision is improved, but off-target effects are worsened
Solution Approach 1:
The patent introduces transposase enzymes as intermediary proteins that mediate between the CRISPR-Cas complex and the target DNA. The transposase acts as a controlled intermediary that only activates DNA insertion when properly guided by the CRISPR complex, reducing spontaneous or off-target genomic modifications while maintaining on-target precision.
Solution Approach 2:
The system performs preliminary verification through guide RNA binding and CRISPR-Cas complex formation before activating the transposase-mediated insertion. This preliminary action ensures that only correctly targeted sites are modified, preventing off-target effects by requiring proper recognition and binding events to occur before the actual genomic modification takes place.
3Productivity
If recombinant nucleic acids encoding CRISPR-associated transposases are used, then recombination rates are improved, but complexity of the system is worsened
Solution Approach 1:
The patent designs CRISPR-associated transposases with multi-functional capabilities, where a single protein complex performs both targeting (via CRISPR guide RNA) and genomic integration (via transposase activity). This universality reduces the need for separate systems and components, thereby increasing recombination rates while managing overall system complexity through functional integration.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables precise and efficient modification of target nucleic acid sequences in eukaryotic cells, enhancing recombination rates and conferring resistance to diseases, while maintaining specificity and reducing off-target effects.
Implementation Method 1
CRISPR RNAs (crRNAs) associate with CRISPR-associated (Cas) effector proteins to form CRISPR-Cas systems that recognize foreign nucleic acids. CRISPR/Cas9 effector complex cleaves homologous double-stranded DNA sequences known as protospacers in the invading DNA.
Implementation Method 2
Specificity is provided by a 'seed sequence' in the crRNA which is located approximately 12 bases upstream of the PAM, which must be capable of hybridizing with the target sequence.
Data Source
AI summary
Provided herein are systems, methods, and compositions for the modification of target DNA sequences. More particularly, systems, methods, and compositions for editing genomic DNA in eukaryotic cells with a CRISPR-associated transposase are provided. Also provided are vectors and vector systems which encode one or more CRISPR-associated transposases, as well as methods for the design and use of such vectors. Also provided are methods for identifying and validating novel CRISPR-associated transposases.